Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Horm Metab Res ; 45(10): 701-8, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23681753

ABSTRACT

Estrogens are secreted primarily by the ovaries and placenta, by the testes in men and also produced by peripheral steroidogenic conversion. The 3 major naturally occurring estrogens are: 17ß-estradiol (E2), estrone and estriol, of which E2 is the predominant and most active. The actions of E2 are mediated by at least 3 different receptors - the classical ERs (ERα and ERß) and G-protein coupled receptor 30 (GPR30). E2 signaling in cardiomyocytes involves ERα- and ERß-independent pathways, and treatment with the E2 receptor antagonists (Selective Estrogen Receptor Modulators- SERMs), which are agonists of GPR30, inhibits cardiac cell growth. Effects of E2 in preventing endothelial dysfunction, a prerequisite of atherosclerosis, are well recognized. Atherosclerosis involves interaction between the cells of the arterial wall endothelial cells (EC) and vascular smooth muscle cell (VSMC), as well as migration of macrophages into wall tunica media. It is predominantly developed at sites with abnormally high shear stress, such as bifurcations or branching of arteries, initiated by an injury to the endothelium and exposure to atherogenic lipids and toxins, such as those contained in tobacco smoke or infectious agents. Animal studies have shown effects of E2 in preventing atherosclerosis, inflammation and endothelial or vascular dysfunction. Gender differences along this pathogenic pathway have been also described. We review the data from the available animal and human studies, which focus on anti-atherogenic effects of E2. These studies represent evidence, albeit indirect, for an inhibitory effect of E2 on the progression of coronary artery atherosclerosis.


Subject(s)
Atherosclerosis/prevention & control , Estradiol/administration & dosage , Animals , Atherosclerosis/epidemiology , Atherosclerosis/etiology , Diet, Atherogenic/adverse effects , Estrogen Replacement Therapy/statistics & numerical data , Female , Humans , Male , Ovariectomy/adverse effects , Ovariectomy/statistics & numerical data , Risk Factors , Selective Estrogen Receptor Modulators/administration & dosage
3.
Am J Med Genet ; 86(2): 187-93, 1999 Sep 10.
Article in English | MEDLINE | ID: mdl-10449659

ABSTRACT

We report on 3 consecutive sib fetuses, presenting at 13, 12, and 13 weeks of gestation, respectively, with fetal hydrops, limb contractures, and akinesia. Autopsy of the first fetus showed subcutaneous fluid collections and severe degeneration of skeletal muscle. Histologic studies demonstrated massive accumulation of diastase-resistant periodic acid-Schiff-positive material in the skeletal muscle cells and epidermal keratinocytes of all 3 fetuses. Enzyme studies of fibroblasts from the 3rd fetus showed deficient activity of glycogen brancher enzyme, indicating that this is a new, severe form of glycogenosis type IV with onset in the early second trimester.


Subject(s)
Glycogen Storage Disease Type IV/genetics , Hydrops Fetalis/pathology , Muscular Diseases/pathology , 1,4-alpha-Glucan Branching Enzyme/metabolism , Adult , Age of Onset , Family Health , Fatal Outcome , Female , Genetic Variation , Gestational Age , Glycogen Storage Disease Type IV/enzymology , Humans , Hydrops Fetalis/genetics , Muscle, Skeletal/pathology , Muscle, Skeletal/ultrastructure , Muscular Diseases/congenital , Muscular Diseases/genetics , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...